Relay Therapeutics(RLAY)
$19.72-0.22 (-1.10%)
RLAY
Relay Therapeutics financials statements
$19.72
At close:-0.22 (-1.10%)
Want to see RLAY full AI Analyst Report?
Relay Therapeutics (RLAY) Ratios
636 Followers
Relay Therapeutics Ratios
RLAY's free cash flow for Q3 2026 was $-63.93M. For the 2026 fiscal year, RLAY's free cash flow was increased by $0.00 and operating cash flow was $-63.93M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 22.61 | 15.95 | 25.44 | 16.00 | 40.14 |
| Quick Ratio | 22.61 | 15.95 | 25.44 | 15.81 | 40.14 |
| Cash Ratio | 3.28 | 2.45 | 4.75 | 15.68 | 11.52 |
| Solvency Ratio | -5.03 | -3.55 | -3.66 | -1.91 | -3.25 |
| Operating Cash Flow Ratio | -9.21 | -4.91 | -9.92 | -3.60 | -3.06 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 524.01M | $ 715.70M | $ 678.13M | $ 869.95M | $ 865.61M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.05 | 0.06 | 0.06 | 0.05 | 0.02 |
| Debt-to-Equity Ratio | 0.06 | 0.06 | 0.07 | 0.06 | 0.03 |
| Debt-to-Capital Ratio | 0.05 | 0.06 | 0.07 | 0.06 | 0.02 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.10 | 1.12 | 1.12 | 1.16 | 1.12 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.19 | 0.34 | 0.44 | 0.51 | 0.24 |
| Net Debt to EBITDA | 0.19 | 0.20 | 0.24 | 3.07 | 1.15 |
| Profitability Margins | |||||
| Gross Profit Margin | 76.83% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBIT Margin | -1800.58% | -3854.04% | -1485.25% | -22516.44% | -7494.45% |
| EBITDA Margin | -1777.41% | -3799.44% | -1464.62% | -22217.38% | -7364.87% |
| Operating Profit Margin | -1971.59% | -3722.07% | -1460.11% | -21670.89% | -12040.21% |
| Pretax Profit Margin | -1800.58% | -3374.72% | -1338.66% | -21036.13% | -12012.94% |
| Net Profit Margin | -1800.58% | -3374.72% | -1338.66% | -21036.13% | -12012.94% |
| Continuous Operations Profit Margin | -1800.58% | -3374.72% | -1338.66% | -21036.13% | -12012.94% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 91.33% | 90.67% | 91.68% | 97.07% | 99.77% |
| Return on Assets (ROA) | -44.50% | -38.76% | -40.52% | -26.42% | -36.08% |
| Return on Equity (ROE) | -48.76% | -43.42% | -45.47% | -30.57% | -40.53% |
| Return on Capital Employed (ROCE) | -50.82% | -45.39% | -45.84% | -28.89% | -37.06% |
| Return on Invested Capital (ROIC) | -50.50% | -45.08% | -45.56% | -28.77% | -36.99% |
| Return on Tangible Assets | -44.50% | -38.86% | -40.63% | -26.47% | -36.17% |
| Earnings Yield | -19.05% | -57.37% | -25.34% | -17.33% | -12.45% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.26 | 0.61 |
| Payables Turnover | 0.46 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.37 | 0.17 | 0.37 | 0.02 | 0.11 |
| Asset Turnover | 0.02 | 0.01 | 0.03 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.02 | 0.01 | 0.03 | 0.00 | 0.00 |
| Cash Conversion Cycle | -790.65 | 0.00 | 0.00 | 1379.39 | 595.28 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 1379.39 | 595.28 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 790.65 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 1379.39 | 595.28 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.37 | -1.74 | -2.45 | -2.04 | -0.78 |
| Free Cash Flow Per Share | -1.37 | -1.76 | -2.48 | -2.13 | -0.82 |
| Dividend Paid and CapEx Coverage Ratio | -574.28 | -123.44 | -72.79 | -25.32 | -21.44 |
| Capital Expenditure Coverage Ratio | -574.28 | -123.44 | -72.79 | -25.32 | -21.44 |
| Operating Cash Flow Coverage Ratio | -7.25 | -5.14 | -5.62 | -3.97 | -3.25 |
| Operating Cash Flow to Sales Ratio | -15.33 | -24.89 | -11.76 | -166.18 | -24.56 |
| Free Cash Flow Yield | -16.25% | -42.66% | -22.56% | -14.23% | -2.67% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -5.25 | -1.75 | -3.95 | -5.77 | -8.03 |
| Price-to-Sales (P/S) Ratio | 94.54 | 58.82 | 52.83 | 1214.17 | 964.56 |
| Price-to-Book (P/B) Ratio | 2.56 | 0.76 | 1.79 | 1.76 | 3.25 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -6.15 | -2.34 | -4.43 | -7.03 | -37.52 |
| Price-to-Operating Cash Flow Ratio | -6.17 | -2.36 | -4.49 | -7.31 | -39.27 |
| Price-to-Earnings Growth (PEG) Ratio | 0.17 | 0.11 | -0.51 | 0.18 | -0.16 |
| Enterprise Value Multiple | -5.13 | -1.35 | -3.37 | -2.40 | -11.94 |
| Enterprise Value | 1.40B | 512.83M | 1.26B | 735.60M | 2.66B |
| EV to EBITDA | -5.13 | -1.35 | -3.37 | -2.40 | -11.94 |
| EV to Sales | 91.18 | 51.25 | 49.30 | 532.65 | 879.64 |
| EV to Free Cash Flow | -5.94 | -2.04 | -4.14 | -3.08 | -34.21 |
| EV to Operating Cash Flow | -5.95 | -2.06 | -4.19 | -3.21 | -35.81 |
| Tangible Book Value Per Share | 3.30 | 5.43 | 6.12 | 8.45 | 9.41 |
| Shareholders’ Equity Per Share | 3.30 | 5.44 | 6.13 | 8.47 | 9.44 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.09 | 0.07 | 0.21 | 0.01 | 0.03 |
| Net Income Per Share | -1.61 | -2.36 | -2.79 | -2.59 | -3.82 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 0.88 | 0.90 | 0.93 | 1.60 |
| Research & Development to Revenue | 17.02 | 31.89 | 12.92 | 178.39 | 57.00 |
| SG&A to Revenue | 3.69 | 7.65 | 2.93 | 47.78 | 18.95 |
| Stock-Based Compensation to Revenue | 4.07 | 9.41 | 3.37 | 40.65 | 16.00 |
| Income Quality | 0.85 | 0.74 | 0.88 | 0.79 | 0.20 |
Currency in USD
